Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial

Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1–3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This phase I trial evaluated pharmacokinetics/pharmacodynamics (PK/PD) characteristics, preliminary safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Ting, Zhang, Le, Shi, Yehui, Bai, Guiying, Pan, Yueyin, Shen, Aizong, Han, Xinghua, Yang, Zhaoyi, Chen, Mingxia, Zhou, Hui, Luo, Yang, Zheng, Shirui, Ba, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663244/
https://www.ncbi.nlm.nih.gov/pubmed/37889382
http://dx.doi.org/10.1007/s10637-023-01396-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663244/
https://www.ncbi.nlm.nih.gov/pubmed/37889382
http://dx.doi.org/10.1007/s10637-023-01396-x

Ejemplares similares